# Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 Years

> **NCT01193400** · PHASE2 · TERMINATED · sponsor: **PETHEMA Foundation** · enrollment: 75 (estimated)

## Conditions studied

- Acute Myelogenous Leukemia

## Interventions

- **DRUG:** Clofarabine
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT01193400
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-09
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2014-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01193400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01193400, "Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 Years". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01193400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*